Subscribe To
Intellia's (ntla) hae candidate gets ema's prime designation
The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA...
October 16, 2023, 2:17 pm
Intellia therapeutics receives priority medicines (prime) designation from the european medicines agency for ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioe
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focuse...
October 13, 2023, 12:38 pm
Intellia therapeutics receives priority medicines (prime) designation from the european medicines agency for ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioe
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focuse...
October 13, 2023, 12:38 pm
Pharvaris to present at the apaaaci 2023 international conference
ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor a...
October 13, 2023, 6:50 am
Alnylam to scrap snda for patisiran after receiving fda complete response letter
Alnylam Pharmaceuticals Inc. ALNY, -1.00% said Monday it would no longer pursue its supplemental new drug application (sNDA) for patisiran as a treatm...
October 9, 2023, 7:43 am
Pharvaris to present at the ciic fall 2023 conference
ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor a...
October 4, 2023, 7:34 am
Why invitae stock popped today
Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common hereditary Can...
October 2, 2023, 4:20 pm
Pharvaris to participate in the 2023 cantor global healthcare conference
ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor ...
September 19, 2023, 6:50 am
Biocryst pharmaceuticals rallies on quebec reimbursement for orladeyo angioedema treatment
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares jumped in early Monday trading after it told investors that the Institut national d'excellence en santé...
September 18, 2023, 10:53 am
Is congestive heart failure hereditary?
Congestive heart failure may be caused by conditions that pass in a family from generation to generation. Healthy lifestyle habits and getting medical...
September 9, 2023, 6:14 am
Pharvaris to present at the 18th german allergy congress
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor ...
September 6, 2023, 6:51 am
Pharvaris to participate in the morgan stanley 21st annual global healthcare conference
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor ...
September 6, 2023, 6:50 am
: regeneron gets fda green light on first treatment for life-threatening immune disease
Regeneron Pharmaceuticals Inc. REGN said Friday that the U.S. Food and Drug Administration has approved its treatment for CHAPLE disease, a rare and l...
August 18, 2023, 6:11 pm
Regeneron gets fda green light on first treatment for life-threatening immune disease
Regeneron Pharmaceuticals Inc. REGN, +0.55% said Friday that the U.S. Food and Drug Administration has approved its treatment for CHAPLE disease, a ra...
August 18, 2023, 2:11 pm
Is vertex pharmaceuticals stock a buy now?
Vertex Pharmaceuticals is diversifying from making solely cystic fibrosis drugs. It could soon commercialize a pair of gene therapies for ...
August 9, 2023, 5:35 am
Solve gne raises $2.5 million, secures leading researchers to help develop cure for hibm
LOS ANGELES, July 31, 2023 (GLOBE NEWSWIRE) — Solve GNE, a Los Angeles based non-profit organization, has raised over $2.5 million and negotiated sp...
July 31, 2023, 6:42 pm
Astria (atxs) rises 5% on fast track tag for angioedema drug
Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to t...
July 21, 2023, 9:12 am
Biocryst selects er-kim pharmaceuticals as commercial partner for orladeyo® (berotralstat) in turkey
RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered...
July 19, 2023, 11:00 am
Ionis (ions) posts encouraging data from amyloidosis drug study
Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for ...
July 11, 2023, 11:03 am
Kalvista (kalv) surges 15% on update from angioedema study
KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of ...
July 10, 2023, 11:00 am